Collastat Absorbable Collagen Hemostatic Sponge
Integra LifeSciences Corporation · Decision date May 27, 2026
What did the FDA decide?
FDA records P810006/S113 as a supplement to PMA P810006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 27, 2026.
FDA approval order statement
an extension of Dirty Hold Time (DHT) for equipment used in cutting collagen during the manufacture of absorbable collagen products, and the installation of a new Clean Compressed Air Point of Use utility in the alternative ISO 8 Cleanroom
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- May 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P810006/S113
- Regulatory pathway
- PMA supplement
- Applicant
- Integra LifeSciences Corporation
- Product code
- LMF
- Decision code
- OK30
- Decision date
- May 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- Integra LifeSciences Corporation
- Product code
- LMF
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P810006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P810006 · Original PMA
COLLASTAT
P810006/S113 received
Application receipt date recorded by FDA.
P810006/S113 · FDA decision
30-Day Notice
P810006/S114 · Related supplement
Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Fo
P810006/S115 · Related supplement
Collastat Absorbable Collagen Hemostatic Sponge and Collastat Absorbable Collagen Hemostatic Agent - Microfibrillar Fo
Timeline entries are records held by MedtechLedger for P810006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P810006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COLLASTATP810006 | Integra LifeSciences Corporation | PMA approval | Dec 10, 1981 | FDA |
| Integra LifeSciences Corporation | PMA supplement | Jun 4, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA supplement | Sep 29, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
| Davol Inc., Sub. C. R. Bard, Inc. | PMA supplement | Jul 15, 2026 | FDA | |
| C.R. Bard, Inc. | PMA supplement | Jul 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Integra LifeSciences Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 311 Enterprise Dr., Planisboro, NJ, 08536
Sources and methodology
- Original FDA record: P810006/S113
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


